Previous 10 | Next 10 |
2023-03-09 13:42:09 ET BioXcel Therapeutics, Inc. (BTAI) Q4 2022 Earnings Conference Call March 09, 2023 08:30 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Matt Wiley - Chief Commercial Officer Richard Steinhart - Chief Financial...
2023-03-09 07:03:18 ET BioXcel Therapeutics press release ( NASDAQ: BTAI ): Q4 GAAP EPS of -$1.95 misses by $0.51 . Revenue of $0.24M misses by $0.84M . Cash and cash equivalents totaled $193.7 million at December 31, 2022, compared to $233.0 million at Decem...
IGALMI™ (dexmedetomidine) commercial execution fully underway in 2023 with key focus on market access and demand generation through expanded field team Multiple pivotal data readouts for BXCL501 expected in Q2 2023 in disease areas with 139 million agitation episodes, 1- ...
NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter ...
NEW HAVEN, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel ...
Summary BioXcel has just published top-line data from the Phase IIa trial of BXCL701 for mSCNC with very promising results. These results position BXCL701 as a valuable asset for the first time. BioXcel's BXCL501 continues to be tested in 3 different phase III trials, from which res...
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrated composite response rate of 25% in patients with metastatic SCNC-variant castration-resistant prostate cancer Company plans to initiate randomized trial evaluating BXCL701 plus pembrolizumab versus BXCL701 monotherapy NEW HAVEN...
NEW HAVEN, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a Key Opinion Leader (...
Summary BioXcel Therapeutics is a biopharmaceutical firm based in Connecticut that develops therapies for central nervous system and immuno-oncology disorders. Its lead products are IGALMI and BXCL701, with IGALMI having received FDA approval. IGALMI is a sublingual thin film formul...
Summary IGALMI's second full launch quarter is underway; expect modest revenues and increasing expenses for the balance of 2023. IGALMI's label supervision, and its approval letter postmarketing requirements, both merit investor consideration. BioXcel's strong late-stage pipeline sh...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...